Donovan Joanne M. - 12 Aug 2026 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Reporting relationship: CMO
Issuer ticker: EWTX
Reported as of: 12 Aug 2026
Net transaction value: -$412,703
SEC form: 4
Accepted by SEC: 14 Aug 2026, 16:54:16 UTC
Prior SEC filing: 05 May 2026
Source filing: View source filing
Reporting owner signature: John R. Moore Attorney-in-Fact for Donovan Joanne M.

Key filing fact

Donovan Joanne M. filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 14 Aug 2026.

Key facts

This page summarizes Donovan Joanne M.'s Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
11 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 14 Aug 2026, 16:54.

Change

Previous filing in this sequence was filed on 05 May 2026.
Current net transaction value: -$412,703.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001644087 Primary reporting owner

Donovan Joanne M.

Relationship: CMO
Address: C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET, BOULDER
Signature: John R. Moore Attorney-in-Fact for Donovan Joanne M.
Signature date: 13 Aug 2026

This filing has been restated. Open the amended filing.

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EWTX transaction

Common Stock

Options Exercise

Transaction value
Shares: +5,781
Change %: +110%
Price: $0.000000^*
Shares after: 11,035
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F1

EWTX transaction

Common Stock

Options Exercise

Transaction value
Shares: +7,031
Change %: +64%
Price: $0.000000^*
Shares after: 18,066
Date: 12 Aug 2026
Ownership: Direct

EWTX transaction

Common Stock

Sale

Transaction value: $124,303
Shares: -2,839
Change %: -16%
Price: $43.78
Shares after: 15,227
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F2, F3

EWTX transaction

Common Stock

Sale

Transaction value: $121,463
Shares: -2,779
Change %: -18%
Price: $43.71
Shares after: 12,448
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F2, F4

EWTX transaction

Common Stock

Sale

Transaction value: $4,620
Shares: -104
Change %: -0.84%
Price: $44.43
Shares after: 12,344
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F2, F5

EWTX transaction

Common Stock

Sale

Transaction value: $35,614
Shares: -800
Change %: -6.5%
Price: $44.52
Shares after: 11,544
Date: 12 Aug 2026
Ownership: Direct
Footnotes: F2, F6

EWTX transaction

Common Stock

Sale

Transaction value: $126,704
Shares: -2,919
Change %: -25%
Price: $43.41
Shares after: 8,625
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F7, F8

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EWTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -5,781
Change %: -33%
Price: $0.000000^*
Shares after: 11,563
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,781
Exercise price: $0.000000
Footnotes: F9

EWTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -7,031
Change %: -25%
Price: $0.000000^*
Shares after: 21,094
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,031
Exercise price: $0.000000
Footnotes: F10

EWTX transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +32,500
Change %
Price: $0.000000^*
Shares after: 32,500
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 32,500
Exercise price: $0.000000
Footnotes: F11

EWTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +65,000
Change %
Price: $0.000000^*
Shares after: 65,000
Date: 12 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 65,000
Exercise price: $0.000000
Footnotes: F12

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 12 footnotes

Footnote F1

Includes 887 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

Footnote F10

Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

Footnote F11

Footnote F12

1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Footnote F2

Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

Footnote F3

The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.23 to $44.20, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.37 to $44.21, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.42 to $44.43, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F6

The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.43 to $44.57, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F7

The sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.

Footnote F8

The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.12 to $43.75, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F9